Shots:

• Corlieve to receive $55M upfront in cash and is eligible to receive $52.1M as development milestones for P-I/II and $191M for P-III development and the approvals of AMT-260 in the US and EU. the transaction is anticipated to be completed in Q3’21
• The acquisition will foster Corlieve lead program- AMT-260- and allows to expands uniQure’s pipeline of innovative gene therapies to treat neurological disorders by using miRNA Silencing Technology
• Corlieve has a license agreement with REGENXBIO that includes an exclusive license to AAV9 for the specific genetic target of AMT-260. REGENXBIO received equity in Corlieve and is eligible to receive milestone payments & royalties on net sales of AMT-260

Ref: Globe Newswire | Image: PR Newswire